IA
RPRX icon

IFP Advisors’s Royalty Pharma RPRX Stock Holding History

IFP Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.6K Buy
1,188
+861
+263% +$44.8K ﹤0.01% 2221
2026
Q1 		$15.7K Buy
327
+228
+230% +$9.99K ﹤0.01% 2913
2025
Q4 		$3.83K Buy
99
+11
+13% +$419 ﹤0.01% 3550
2025
Q3 		$3.1K Buy
+88
New +$3.19K ﹤0.01% 3495
2025
Q2 		– Sell
-326
Closed -$10.8K – 2464
2025
Q1 		$10.2K Sell
326
-171
-34% -$5.42K ﹤0.01% 2572
2024
Q4 		$12.7K Buy
497
+324
+187% +$8.59K ﹤0.01% 2442
2024
Q3 		$4.9K Sell
173
-72
-29% -$1.99K ﹤0.01% 2672
2024
Q2 		$6.46K Buy
245
+60
+32% +$1.66K ﹤0.01% 2488
2024
Q1 		$5.63K Buy
185
+22
+13% +$649 ﹤0.01% 2422
2023
Q4 		$4.6K Buy
163
+79
+94% +$2.17K ﹤0.01% 2454
2023
Q3 		$2.29K Buy
84
+13
+18% +$386 ﹤0.01% 2793
2023
Q2 		$2.18K Sell
71
-489
-87% -$16.6K ﹤0.01% 2848
2023
Q1 		$24.9K Buy
560
+229
+69% +$8.49K ﹤0.01% 1923
2022
Q4 		$15K Buy
331
+17
+5% +$710 ﹤0.01% 3122
2022
Q3 		$14K Buy
314
+2
+0.6% +$85 ﹤0.01% 3407
2022
Q2 		$14K Hold
312
– – ﹤0.01% 3160
2022
Q1 		$14K Buy
312
+302
+3,020% +$11.9K ﹤0.01% 3160
2021
Q4 		$1K Buy
+10
New +$388 ﹤0.01% 3102
2021
Q1 		– Sell
-38
Closed -$1.8K – 3200
2020
Q4 		$2K Sell
38
-812
-96% -$34.5K ﹤0.01% 2651
2020
Q3 		$36K Buy
850
+450
+113% +$19.3K ﹤0.01% 1406
2020
Q2 		$19K Buy
+400
New +$19.8K ﹤0.01% 1588

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's RPRX Position: Q2 2026 in Review

IFP Advisors increased its Royalty Pharma (RPRX) stake by 263% in Q2 2026, buying an estimated $44.8K and bringing the position to 1,188 shares worth $66.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.

IFP Advisors first reported a position in RPRX in Q2 2020 and has held it in 21 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • IFP Advisors held 1,188 shares of Royalty Pharma worth $66.6K as of Q2 2026.
  • IFP Advisors bought 861 Royalty Pharma shares in Q2 2026, an estimated $44.8K.
  • Royalty Pharma made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2221 holding.
  • IFP Advisors first reported a position in Royalty Pharma in Q2 2020 and has held it in 21 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.